Trials / Conditions / PD-L1 Gene Mutation

PD-L1 Gene Mutation

9 registered clinical trials studyying PD-L1 Gene Mutation — 2 currently recruiting.

Status	Trial	Sponsor	Phase
Recruiting	TRIMPACT: Real-World First-Line Atezolizumab Use in Stage IV NSCLC With PD-L1 ≥50% NCT07279402	Antalya Training and Research Hospital	—
Recruiting	Clinical Efficacy of Tumour Treatment Vaccine (TTV) Combined With PD-1 in the Treatment of Relapsed Refractory NCT06430502	Wuxi People's Hospital	N/A
Completed	Study to Evaluate Safety, Tolerance and Efficacy of ASC22 Combined With ART in Subjects With HIV NCT05330143	Ascletis Pharmaceuticals Co., Ltd.	Phase 2
Terminated	Sitravatinib Plus Pembrolizumab in Patients With Advanced Treatment-Naïve PD-L1+ Non-Squamous NSCLC NCT04925986	Sarah Goldberg	Phase 2
Withdrawn	Radiotherapy in Combo With Chemo and Immunotherapy in Patients With PD-L1 Positive Metastatic TNBC NCT05233696	University of Colorado, Denver	Phase 2
Withdrawn	Study of Durvalumab or Durvalumab Plus Chemotherapy in Kras Mutation Positive and PD-L1 High (≥ 50%) NSCLC Pat NCT04470674	Shirish M Gadgeel	Phase 2
Withdrawn	Study of Pembrolizumab With Single Agent Chemotherapy in Elderly Patients With Advanced NSCLC NCT04754815	Shirish Gadgeel	Phase 2
Active Not Recruiting	Treating Early-stage Non-Small Cell Lung Cancer With Durvalumab and Radiation Therapy NCT04716946	Memorial Sloan Kettering Cancer Center	Phase 2
Unknown	Atezolizumab Plus CArboplatin Plus Nab-paclitaxel NCT05266937	Consorzio Oncotech	Phase 2